Sentinel Lymph Node Biopsy for Melanoma: Controversy Despite Widespread Agreement
Authors:
- Kelly M. McMastersKMKelly M. McMasters
- Douglas S. ReintgenDRDouglas S. Reintgen
- Merrick I. RossMRMerrick I. Ross
- Jeffrey E. GershenwaldJGJeffrey E. Gershenwald
- Michael J. EdwardsMEMichael J. Edwards
- Arthur SoberASArthur Sober
- Neil FenskeNFNeil Fenske
- Frank GlassFGFrank Glass
- Charles M. BalchCBCharles M. Balch
- Daniel G. CoitDCDaniel G. Coit
- 1 June 2001
- journal article
- review article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 19 (11) , 2851-2855
Abstract
Although sentinel lymph node (SLN) biopsy for melanoma has been adopted throughout the United States and abroad as a standard method of determining the pathologic status of the regional lymph nodes, some controversy still exists regarding the validity and utility of this procedure. SLN biopsy is a minimally invasive procedure, performed on an outpatient basis at the time of wide local excision of the melanoma, with little morbidity. Numerous studies have documented the accuracy of this procedure for identifying nodal metastases. There are four major reasons to perform SLN biopsy. First, SLN biopsy improves the accuracy of staging and provides valuable prognostic information for patients and physicians to guide subsequent treatment decisions. Second, SLN biopsy facilitates early therapeutic lymph node dissection for those patients with nodal metastases. Third, SLN biopsy identifies patients who are candidates for adjuvant therapy with interferon alfa-2b. Fourth, SLN biopsy identifies homogeneous patient populations for entry onto clinical trials of novel adjuvant therapy agents. Overall, the benefit of accurate nodal staging obtained by SLN biopsy far outweighs the risks and has important implications for patient management.Keywords
This publication has 25 references indexed in Scilit:
- The argument against sentinel node biopsy for malignant melanomaBMJ, 2000
- High- and Low-Dose Interferon Alfa-2b in High-Risk Melanoma: First Analysis of Intergroup Trial E1690/S9111/C9190Journal of Clinical Oncology, 2000
- Long-Term Results of a Multi-Institutional Randomized Trial Comparing Prognostic Factors and Surgical Results for Intermediate Thickness Melanomas (1.0 to 4.0 mm)Annals of Surgical Oncology, 2000
- Regional nodal surgery for melanoma impacts recurrence rates and survival.Annals of Surgical Oncology, 2000
- Standardized probe-directed sentinel node dissection in melanomaSurgery, 2000
- Immediate or delayed dissection of regional nodes in patients with melanoma of the trunk: a randomised trialThe Lancet, 1998
- Efficacy of an Elective Regional Lymph Node Dissection of 1 to 4 mm Thick Melanomas for Patients 60 Years of Age and YoungerAnnals of Surgery, 1996
- Intraoperative Radiolymphoscintigraphy Improves Sentinel Lymph Node Identification for Patients with MelanomaAnnals of Surgery, 1996
- The Orderly Progression of Melanoma Nodal MetastasesAnnals of Surgery, 1994
- Technical Details of Intraoperative Lymphatic Mapping for Early Stage MelanomaArchives of Surgery, 1992